Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events

Ryuji Kato(Nagoya University), Yoshio Ijiri(Osaka University of Pharmaceutical Sciences)
˜Die œPharmazie
February 1, 2022
Cited by 4


Related Papers